Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease

2019/01/18 by Laurent Castéra, Laurent Castera, Mireen Friedrich-Rust +2 · 30 citations
Medicine · #Liver Disease Diagnosis and Treatment #Diet, Metabolism, and Disease #Liver Disease and Transplantation

paper · pdf · doi:10.1053/j.gastro.2018.12.036

Cited by

• The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
• The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study
• Liver fibrosis is associated with an increased risk of non‐fatal myocardial infarction
• AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis
• Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases
• Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. [europepmc]
• Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). [europepmc]
• Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. [europepmc]
• AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. [europepmc]
• Limitations of non-invasive tests for assessment of liver fibrosis. [europepmc]
• The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. [europepmc]
• NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. [europepmc]
• The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. [europepmc]
• MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. [europepmc]
• Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. [europepmc]
• Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. [europepmc]
• KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. [europepmc]
• The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. [europepmc]
• Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice. [europepmc]
• Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. [europepmc]
• NAFLD in the Elderly. [europepmc]
• Non-alcoholic fatty liver disease: A patient guideline. [europepmc]
• Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. [europepmc]
• Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. [europepmc]
• NAFLD: Mechanisms, Treatments, and Biomarkers. [europepmc]
• Association between SII and hepatic steatosis and liver fibrosis: A population-based study. [europepmc]
• Associations between life's essential 8 and non-alcoholic fatty liver disease among US adults. [europepmc]
• AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. [europepmc]
• Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults. [europepmc]
• Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD. [europepmc]